- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.05. | NFL BIOSCIENCES S.A.: NFL Biosciences announces the success of its capital increase capped at €3 million | 2 | Euronext | ||
| 22.05. | NFL BIOSCIENCES S.A.: NFL Biosciences launches a capital increase of approximately €2.2 million | 1 | Euronext | ||
| 12.05. | NFL BIOSCIENCES S.A.: NFL Biosciences strengthens its scientific committee with world-class experts to support the Phase 3 development of NFL-101, its first-in-class therapy for tobacco addiction | 1 | Euronext | ||
| 05.05. | NFL BIOSCIENCES S.A.: NFL Biosciences announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity | 1 | Euronext | ||
| NFL BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 24.04. | NFL BIOSCIENCES S.A.: Marex Group initiates coverage of NFL Biosciences with a Buy rating | 2 | Euronext | ||
| 11.04. | NFL BIOSCIENCES S.A.: NFL Biosciences presents its 2024 annual results and provides an update on its clinical program | 1 | Euronext | ||
| 24.03. | NFL BIOSCIENCES S.A.: NFL Biosciences presents the immunological analysis results of its phase 2 CESTO II study confirming the efficacy of NFL-101, its first-in-class treatment for tobacco addiction | 1 | Euronext | ||
| 05.03. | NFL BIOSCIENCES S.A.: NFL Biosciences publishes its 2025 financial agenda | 1 | Euronext | ||
| 04.02. | NFL BIOSCIENCES S.A.: NFL Biosciences publishes positive results from a complementary program confirming the excellent safety profile of NFL-101, its first-in-class treatment for tobacco addiction | 1 | Euronext |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| BIONTECH | 99,30 | +1,85 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
| DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| QIAGEN | 40,300 | -0,06 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
| 89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
| ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
| KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 7,030 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings |
NFL BIOSCIENCES SA gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,100 Euro und damit -0,90 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NFL BIOSCIENCES SA finden Sie auf Wallstreet Online.